Palvella Therapeutics posts new investor presentation

Palvella Therapeutics, Inc. filed a current report to note that it has posted a new corporate presentation on its website.

Rhea-AI Filing Summary

Palvella Therapeutics, Inc. filed a current report to note that it has posted a new corporate presentation on its website. The presentation, dated January 29, 2026 and filed as Exhibit 99.1, will be used by company representatives in various investor meetings.

The filing does not introduce new financial results or major transactions, but formally makes the investor presentation part of the public record by incorporating it by reference into the report.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Palvella Therapeutics (PVLA) disclose in its latest 8-K?

Palvella Therapeutics disclosed that it posted a new corporate presentation on its website. The presentation, dated January 29, 2026, is filed as Exhibit 99.1 and will be used in various investor meetings, becoming part of the official public record.

What is included in Exhibit 99.1 of Palvella Therapeutics 8-K filing?

Exhibit 99.1 contains Palvella Therapeutics corporate presentation dated January 29, 2026. Company representatives plan to use this presentation in meetings with investors, and the document is incorporated by reference, meaning it is treated as part of the main disclosure.

Why did Palvella Therapeutics (PVLA) file an 8-K about a corporate presentation?

Palvella Therapeutics filed the 8-K to formally notify investors that a new corporate presentation is available and being used in investor meetings. By filing it as Exhibit 99.1, the company ensures the same information is accessible to all market participants simultaneously.

Where can investors find the new Palvella Therapeutics corporate presentation?

Investors can find Palvella Therapeutics new corporate presentation on the companys website. The same presentation, dated January 29, 2026, is also available as Exhibit 99.1 to the 8-K, providing a publicly filed copy through the SECs EDGAR system.

Does Palvella Therapeutics 8-K include new financial statements or deals?

The 8-K does not include new financial statements or major transactions. It primarily serves to file and reference a corporate presentation dated January 29, 2026, which will be used in investor meetings and is attached as Exhibit 99.1 to the report.

Who signed the latest Palvella Therapeutics (PVLA) 8-K filing?

The 8-K was signed on behalf of Palvella Therapeutics by Matthew Korenberg. He signed in his capacity as Chief Financial Officer, confirming the companys authorization of the filing related to the new corporate investor presentation dated January 29, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/29/2026 - 04:08 PM EST Learn about SEC filing dates

false000158364800015836482026-01-292026-01-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 29, 2026

PALVELLA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Nevada			001-37471	30-0784346
(State or other jurisdiction of incorporation)			(Commission File Number)	(IRS Employer Identification No.)
353 W. Lancaster Ave, Suite 200
Wayne, Pennsylvania				19087
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code: (484) 253-1461

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, $0.001 par value per share		PVLA		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On January 29, 2026, Palvella Therapeutics, Inc. (the “Company”) posted a corporate presentation to its website, which representatives of the Company will use in various meetings with investors from time to time. A copy of the presentation is filed herewith as Exhibit 99.1, and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Corporate Presentation of Palvella Therapeutics, Inc., dated January 29, 2026*
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			PALVELLA THERAPEUTICS, INC.
Date:	January 29, 2026	By:	/s/ Matthew Korenberg
			Matthew Korenberg
			Chief Financial Officer